Low-density lipoprotein clearance in patients with chronic renal failure. 2009

Helena Kastarinen, and Sohvi Hörkkö, and Heikki Kauma, and Anna Karjalainen, and Markku J Savolainen, and Y Antero Kesäniemi
Institute of Clinical Medicine, Department of Internal Medicine, Biocenter Oulu, Oulu, Finland.

BACKGROUND Chronic renal failure increases the risk of atherosclerosis. The clearance of low-density lipoprotein (LDL), a major risk factor for atherosclerosis, has been reported as being disturbed in dialysis patients. We studied LDL metabolism in non-dialyzed patients with chronic kidney disease (CKD). METHODS LDL clearance was studied with a radiotracer method in 57 CKD patients and 10 healthy controls. RESULTS In the CKD patients, the fractional catabolic rate of LDL apo B (LDL FCR), an indicator of LDL clearance from plasma, ranged from 0.13 to 0.56 pools/day with a mean value of 0.34 pools/day being comparable to that of the control subjects. In the renal patients, LDL FCR correlated significantly with estimated glomerular filtration rate (eGFR) (r = 0.340, P = 0.010) and this association remained significant after the adjustment with age, body mass index, gender, presence of diabetes and LDL cholesterol concentration (P = 0.004). In CKD patients with eGFR <15 mL/min/1.73 m(2) the mean LDL FCR was significantly reduced when compared to that of CKD patients with eGFR >30 mL/min/1.73 m(2) (P = 0.005). LDL apo B production rate was not associated with renal function or different between renal patients and control subjects. CONCLUSIONS The clearance of LDL seems to be related to the severity of renal impairment, but a remarkable reduction in LDL catabolism can be observed only in patients with advanced renal failure.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D055815 Young Adult A person between 19 and 24 years of age. Adult, Young,Adults, Young,Young Adults

Related Publications

Helena Kastarinen, and Sohvi Hörkkö, and Heikki Kauma, and Anna Karjalainen, and Markku J Savolainen, and Y Antero Kesäniemi
February 1994, Kidney international,
Helena Kastarinen, and Sohvi Hörkkö, and Heikki Kauma, and Anna Karjalainen, and Markku J Savolainen, and Y Antero Kesäniemi
August 2008, Pediatrics international : official journal of the Japan Pediatric Society,
Helena Kastarinen, and Sohvi Hörkkö, and Heikki Kauma, and Anna Karjalainen, and Markku J Savolainen, and Y Antero Kesäniemi
September 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Helena Kastarinen, and Sohvi Hörkkö, and Heikki Kauma, and Anna Karjalainen, and Markku J Savolainen, and Y Antero Kesäniemi
January 2003, Nephron. Clinical practice,
Helena Kastarinen, and Sohvi Hörkkö, and Heikki Kauma, and Anna Karjalainen, and Markku J Savolainen, and Y Antero Kesäniemi
November 1997, Medical hypotheses,
Helena Kastarinen, and Sohvi Hörkkö, and Heikki Kauma, and Anna Karjalainen, and Markku J Savolainen, and Y Antero Kesäniemi
February 1993, Metabolism: clinical and experimental,
Helena Kastarinen, and Sohvi Hörkkö, and Heikki Kauma, and Anna Karjalainen, and Markku J Savolainen, and Y Antero Kesäniemi
January 1991, Mineral and electrolyte metabolism,
Helena Kastarinen, and Sohvi Hörkkö, and Heikki Kauma, and Anna Karjalainen, and Markku J Savolainen, and Y Antero Kesäniemi
January 2007, British journal of biomedical science,
Helena Kastarinen, and Sohvi Hörkkö, and Heikki Kauma, and Anna Karjalainen, and Markku J Savolainen, and Y Antero Kesäniemi
January 1997, Nephron,
Helena Kastarinen, and Sohvi Hörkkö, and Heikki Kauma, and Anna Karjalainen, and Markku J Savolainen, and Y Antero Kesäniemi
April 1979, British medical journal,
Copied contents to your clipboard!